COMMUNIQUÉS West-GlobeNewswire

Koelis Announces Partnership and Initial Experience with DeepHealth for AI-powered Prostate MRI Interpretation and Guidance in Fusion Biopsy
20/09/2024
GRENOBLE, France and PRINCETON, N.J., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com ), a global leader and innovator in prostate care, announced today the partnership and [...]
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
20/09/2024
Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic [...]
MESMERIZE brings community pharmacy leaders together to explore industry’s bright future
20/09/2024
NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- MESMERIZE united three knowledge leaders in community pharmacy for an invigorating exchange of ideas, business strategies and patient-focused solutions. Published today, the [...]
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel
20/09/2024
CARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced that on September 11, 2024, the Company received a notice from Nasdaq indicating that the [...]
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
19/09/2024
ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]
ADR Ratio Change
19/09/2024
September 19, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a [...]
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
19/09/2024
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization [...]
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
19/09/2024
Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen’s Iqirvo® (elafibranor) in the U.S. for [...]
GENFIT : Résultats financiers du premier semestre 2024 et point sur les activités de la Société
19/09/2024
Trésorerie et équivalents de trésorerie s’éle vant à 61,6 m illio ns d’euros au 30 juin 2024 n’incluant pas le paiement d’étape de 48,7 millions d’euros facturé en juin 2024 (reçu en août 2024) lors de la première vente [...]
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
19/09/2024
FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S. Phase 3 study for ersodetug for the treatment of tumor HI expected to commence in the first [...]
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/09/2024
SAN FRANCISCO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative [...]
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
19/09/2024
TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial Results to be presented at the American Heart [...]
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
19/09/2024
Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked warrants Altamira [...]
Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
19/09/2024
Analyses of Effects of Aficamten on Key Clinical Outcomes from SEQUOIA-HCM to be Featured in Late Breaking Clinical Trial Presentation at HFSA SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cytokinetics [...]
Rejuveron Life Sciences AG prend le nom de Centenara Labs AG et fait le point sur les dernières données cliniques
19/09/2024
Les actionnaires approuvent le changement de dénomination sociale sous la marque Centenara Labs AG (« Centenara ») Le changement de marque positionne l’entreprise pour des initiatives stratégiques destinées à soutenir [...]
EON Medical & Wellness: Transforming Healthcare for the Hispanic Community Through Cutting-Edge Telehealth
19/09/2024
Revolutionizing Healthcare Access with Culturally Focused, Language-Accessible Care TAMPA, Fla., Sept. 19, 2024 (GLOBE NEWSWIRE) -- EON Medical + Wellness , a pioneering force in healthcare, is making waves in the [...]
Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
19/09/2024
Wegovy ® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function Wegovy ® (semaglutide 2.4 mg) is the first obesity medication to [...]
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
19/09/2024
Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis SOLANA BEACH, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical [...]
Bright Green Corporation Provides an Update, Reinforces Commitment to Shareholders, and Focuses on Growth and Strategic Partnerships
19/09/2024
GRANTS, NEW MEXICO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”), today announced that trading of its shares have been suspended from the Nasdaq Stock [...]

Pages